Gene analysis (tumor protein 53) full sequence analysis
Medicare pricing data for 44 providers across 5 states
Note: These costs reflect the Medicare physician/supplier component. Hospital facility fees are billed separately and can be 2-5x the physician fee.
💡 What You Should Know
Gene analysis (tumor protein 53) full sequence analysis (HCPCS code 81351) is a medical procedure billed to Medicare. The average Medicare-allowed cost is $628.71, but hospitals typically charge $729.35 — a 1.2x markup. Prices vary significantly by state and provider.
🏷️ Typical Out-of-Pocket Cost
Medicare patients typically pay about 20% of the allowed amount as coinsurance. Based on the average allowed cost of $628.71, your out-of-pocket cost would be approximately $125.74. Actual costs depend on your specific plan, deductible, and whether you've met your annual out-of-pocket maximum.
What Hospitals Charge vs. What Medicare Pays
Hospitals charge 1.2x more than what Medicare allows for this procedure. Medicare actually pays $628.71 on average.
Cost by State
Medicare-allowed amounts vary significantly by state
| State | Allowed Cost | Hospital Charge | Providers | Services | vs. National |
|---|---|---|---|---|---|
| New Jersey | $629 | $702 | 4 | 16 | +0.0% |
| Pennsylvania | $629 | $642 | 2 | 14 | +0.0% |
| Florida | $629 | $728 | 27 | 10,296 | +0.0% |
| Tennessee | $605 | $1,284 | 1 | 15 | -3.7% |
| Maryland | $564 | $575 | 1 | 12 | -10.4% |
⚠️ Important: These costs reflect the Medicare physician/supplier component. Hospital facility fees may be billed separately. Total out-of-pocket costs may be higher.
💊 Need post-procedure medications? Check costs on OpenPrescriber